Secondary endpoints
agitation, HT
SIDE EFFECT
The percentage of patients with a favorable functional outcome was approximately the same in both groups. Early neurological recovery on day 14 was more noticeable in the Cerebrolysin group. However, the difference disappeared in patients with HT (Table Secondary endpoint. Modified Rankin Scale score on day 90. No serious AE related to Cerebrolysin were observed. Several mild-to-moderate AE occurred in both groups within 48 h after treatment initiation and lasted up to a few hours without any consequences. The study investigators had unanimously agreed that none of them were attributed to the studied medication, except mild agitation, a well-known side effect of Cerebrolysin (Table Safety analysisFrom day 0 to 14, there were no clinically significant abnormalities in the vital signs and laboratory tests in both groups. Overall, no safety concerns were noted for the concomitant use of IVT and Cerebrolysin.